Physician profile
Ami C Ranani
NPI 1306841838
$11,910.34
in general payments reported to CMS, 2019-2025
26 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,320 · 2020: $964 · 2021: $2,319 · 2022: $586 · 2023: $1,068 · 2024: $357 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,423.99 | 2019-2024 | Dailies, Total30, Rocklatan |
| Coopervision INC. | $2,370.82 | 2019-2024 | Myday Contact Lens, Clariti Contact Lens |
| Eyevance Pharmaceuticals LLC | $1,802.03 | 2019-2021 | |
| Allergan, INC. | $905.98 | 2019-2022 | |
| Oyster Point Pharma, INC. | $443.50 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $406.92 | 2019-2021 | |
| Visioneering Technologies, INC. | $330.05 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $246.61 | 2021-2024 | Acthar |
| Bausch & Lomb Americas INC. | $246.32 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Shire North American Group INC | $228.66 | 2019 | |
| Biotissue Holdings INC. | $204.04 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $199.97 | 2019-2024 | Cequa |
| Sight Sciences, INC. | $198.95 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $181.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $154.89 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $133.92 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Glaukos Corporation | $125.00 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $77.24 | 2019-2020 | |
| Abbvie INC. | $65.50 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $35.90 | 2024 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $30.04 | 2023 | Cirrus Hd-Oct |
| Abb Con-Cise Optical Group LLC | $26.64 | 2020-2021 | |
| Harrow Eye, LLC | $19.19 | 2025 | |
| Carl Zeiss Meditec, INC. | $18.47 | 2019 | |
| Quidel Corporation | $18.26 | 2023 | |
| Horizon Therapeutics Plc | $15.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Ranani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.